Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Small Pharma Inc (OP: DMTTF ) N/A UNCHANGED Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.1117 Today's Range N/A - N/A 52wk Range N/A - N/A Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD January 06, 2024 A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub Via Benzinga Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More October 29, 2023 Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Via Benzinga Topics Intellectual Property Exposures Intellectual Property Performance More News Read More Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents October 26, 2023 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics October 23, 2023 Via Benzinga InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector October 23, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics October 23, 2023 From Cybin Inc. Via Business Wire Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted October 22, 2023 Via Benzinga Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business October 20, 2023 Via Benzinga Small Pharma Reports Fiscal Second Quarter 2024 Highlights October 19, 2023 From Small Pharma Inc. Via GlobeNewswire Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement October 18, 2023 Via Benzinga Small Pharma Obtains Final Order Approving Arrangement October 17, 2023 From Cybin Inc. Via Business Wire Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More October 16, 2023 Via Benzinga Exposures Product Safety Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates October 13, 2023 Via Benzinga Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders October 12, 2023 From Small Pharma Inc. Via GlobeNewswire Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Via Benzinga Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results September 26, 2023 Via Benzinga Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Via Benzinga Topics Economy Exposures Interest Rates Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder September 26, 2023 From Small Pharma Inc. Via GlobeNewswire Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression September 21, 2023 Via Benzinga Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update September 18, 2023 Via Benzinga Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT September 05, 2023 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More September 05, 2023 Via Benzinga Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions August 31, 2023 Via Benzinga Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M August 29, 2023 Via Benzinga Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety August 28, 2023 Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
